SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).

被引：5
|
作者：
Chi, K. N.
De Bono, J. S.
Higano, C. S.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Hosp, Sutton, Surrey, England
[4] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps180
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS180
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C plus DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).
    Al Harthy, Munjid
    Madan, Ravi Amrit
    Karzai, Fatima
    Petrylak, Daniel Peter
    Kim, Joseph W.
    Arlen, Philip M.
    Theoret, Marc Robert
    Marte, Jenn
    Bilusic, Marijo
    Couvillon, Anna
    Chun, Guinevere
    Owens, Helen
    Hankin, Amy
    Cordes, Lisa M.
    Figg, William Douglas
    Gulley, James L.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [3] A safety study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzal, Fatima
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Phillp M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC)
    Karzai, Fatima H.
    Shah, Avani Atul
    Ojemuyiwa, Michelle A.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Dawson, Nancy Ann
    Arlen, Philip M.
    Theoret, Marc Robert
    Wright, John Joseph
    Chen, Clara
    Trepel, Jane B.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Overcoming resistance mechanisms in a study of cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Strauss, Julius
    Chun, Guinevere
    Couvillon, Anna
    Harold, Nancy
    Chen, Clara
    Dawson, Nancy Ann
    Apolo, Andrea Borghese
    Steinberg, Seth M.
    Trepel, Jane B.
    Wright, John Joseph
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] A phase I study of cabozantinib (Cabo) plus docetaxel (D) and prednisone (P) in metastatic castrate resistant prostate cancer (mCRPC).
    Karzai, Fatima H.
    Madan, Ravi Amrit
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Wright, John Joseph
    Trepel, Jane B.
    Beatson, Melony A.
    Harold, Nancy
    Couvillon, Anna
    Steinberg, Seth M.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase I Trial of the Combination of Docetaxel Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer
    Thakur, Manish K.
    Heilbrun, Lance
    Dobson, Kimberlee
    Boerner, Julie
    Stark, Karri
    Li, Jing
    Smith, Daryn
    Heath, Elisabeth
    Fontana, Joseph
    Vaishampayan, Ulka
    CLINICAL GENITOURINARY CANCER, 2018, 16 (03) : E695 - E703
  • [8] A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Zurita, A.
    Shore, N. D.
    Kozloff, M. F.
    Ryan, C. W.
    Beer, T. M.
    Maneval, E. Chow
    Chen, I.
    Logothetis, C. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 287 - 287
  • [9] Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer(CRPC)
    De Souza, P. L.
    Mellado, B.
    Pfister, C.
    Rosenthal, M.
    Castellano, D. E.
    Weber, D.
    Ferrara, S.
    Shaik, N.
    Tan, E.
    Patterson, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
    Green, Angela K.
    Corty, Robert W.
    Wood, William A.
    Meeneghan, Mathew
    Reeder-Hayes, Katherine E.
    Basch, Ethan
    Milowsky, Matthew I.
    Dusetzina, Stacie B.
    ONCOLOGIST, 2015, 20 (05): : 516 - 522
12345